Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)

Rheumatoid Arthritis Clinical Trial

— RA-DRUM  

Official title:

A Multi-center, Open, Randomized, 18-month, Parallel-group, Superiority Study to Compare the Effect of Proactive Therapeutic Drug Monitoring Versus Standard of Care With Regards to Maintenance of Sustained Disease Control Without Flare in Adults With Rheumatoid Arthritis Treated With a Subcutaneous Tumor Necrosis Factor Inhibitor

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06440629
• Other study ID #: EU CT No 2023-510184-35-00
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: June 15, 2024
• Est. completion date: December 31, 2027

Study information

• Verified date: June 2024
• Source: Diakonhjemmet Hospital
• Contact: Ingrid Jyssum, PhD, MD
• Phone: +4722451500
• Email: ingrid.jyssum[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to compare therapeutic drug monitoring (TDM) versus Standard of care in patients with rheumatoid arthritis treated with a subcutaneous tumor necrosis factor inhibitor (adalimumab).

The main question it aims to answer is:

Is TDM superior to standard of care in order to maintain sustained disease control without flares?

Participants will be followed with blood sampling every second month, measuring serum drug levels and anti-drug antibodies of the TNFi. In the TDM-group, the researchers will adjust the dosage of the TNFi based on knowledge on optimal therapeutic ranges. In the Standard of care group, the TNFi will be administered according to standard of care without knowledge of serum drug levels or anti-drug antibodies.

Description:

There is a considerable variation in serum drug levels among rheumatoid arthritis (RA) patients on tumor necrosis factor inhibitors (TNFi), and a high number develop neutralizing anti-drug antibodies (ADAb). Sub-therapeutic drug levels and ADAb formation are major contributors to TNFi treatment failure and disease flare. Proactive therapeutic drug monitoring (TDM), i.e., individualized drug dosing based on regular assessments of serum drug levels and ADAb, has the potential to optimize the efficacy and safety of TNFi treatment.

The aim of the RA-DRUM trial is to assess whether TDM is superior to standard of care in order to maintain sustained disease control without flares in patients with RA treated with the SC TNFi adalimumab.

Participants will be randomized to:

• Administration of TNFi based on proactive TDM (TDM group)

• Administration of TNFi based on standard of care without knowledge of serum drug levels or ADAb status (Standard of care group)

Participants will be followed for 18 months with on-site visits at baseline, 4, 8, 12 and 18 months and digital visits at 2, 6, 10, 14, and 16 months. Blood sampling for serum drug levels and anti-drug antibodies will be done at all visits.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 350
• Est. completion date: December 31, 2027
• Est. primary completion date: December 31, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 74 Years

Eligibility

Inclusion Criteria:

1. A clinical diagnosis of RA

2. = 18 and under 75 years of age at screening

3. On stable therapy with standard dose of a SC TNFi (adalimumab) for a minimum of 3 months and a maximum of 24 months

4. In low disease activity or remission (DAS28-CRP under 3.2) and indication for continuation of treatment according to the treating physician

5. Subject capable of understanding and signing an informed consent form

Exclusion Criteria:

1. Major comorbidities, such as previous malignancies within the last 5 years, uncontrolled diabetes mellitus, severe infections (including HIV), uncontrollable hypertension, severe cardiovascular disease (NYHA class 3 or 4), severe respiratory diseases, demyelinating disease, significant chronic widespread pain syndrome, significant renal or hepatic disease, and/or other diseases or conditions which either contraindicate treatment with SC TNFi or make adherence to the protocol difficult

2. Hypersensitivity to sc TNFi (adalimumab).

3. Pregnancy, or subject considering becoming pregnant during the study period

4. Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers, or other factors that makes adherence to the study protocol difficult

5. Changes in csDMARD co-medication, including dose changes of csDMARD or changes in the dose of corticosteroids within the last 2 months

6. Co-medication with bDMARD, tsDMARD, or other immunosuppressive drugs (excluding csDMARD and corticosteroids = 7.5 mg prednisolone (or equivalent) once daily).

7. Active participation in any other interventional study.

8. In need of live vaccines during the study period.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Drug:
• Therapeutic drug monitoring (TDM) of adalimumab
In the TDM-group, the adalimumab dose will be adjusted according to the following algorithms in order to keep the drug level within the therapeutic range: Serum drug level within therapeutic range : keep dose Low drug levels, ADAb undetectable or low levels : Decrease dosing interval by one week to a maximum of 40 mg/week Low drug levels, ADAb high levels : Switch to another therapy High drug levels : Increase dosing interval by one week up to a maximum of 6 weeks

Locations

Country	Name	City	State
Austria	Medical University Vienna	Vienna
Norway	Ålesund Hospital	Ålesund
Norway	Haukeland University Hospital	Bergen
Norway	Nordland Hospital Trust	Bodø
Norway	Drammen Hospital	Drammen
Norway	Førde Hospital Trust	Førde
Norway	Haugesund Rheumatism Hospital	Haugesund
Norway	Hospital of Southern Norway Trust	Kristiansand
Norway	Lillehammer Hospital for Rheumatic Diseases	Lillehammer
Norway	Helgeland Hospital Trust	Mo I Rana
Norway	Østfold Hospital Trust	Moss
Norway	Diakonhjemmet sykehus	Oslo	N-0319
Norway	Martina Hansen's Hospital	Sandvika
Norway	Betanien Hospital	Skien
Norway	Stavanger University Hospital	Stavanger
Norway	University Hospital of North Norway	Tromsø
Norway	St.Olavs Hospital	Trondheim
Sweden	Karolinska University Hospital	Stockholm
United Kingdom	Queen Mary	London	Sw15 5pn

Sponsors (20)

Lead Sponsor

Collaborator

Diakonhjemmet Hospital

Alesund Hospital, Betanien Hospital, Drammen sykehus, Førde Hospital Trust, Haugesund Rheumatism Hospital, Haukeland University Hospital, Helgeland Hospital Trust, Helse Stavanger HF, Hospital of Southern Norway Trust, Karolinska University Hospital, Lillehammer Hospital for Rheumatic Diseases, Martina Hansen's Hospital, Medical University of Vienna, Nordlandssykehuset HF, Oslo University Hospital, Ostfold Hospital Trust, Queen Mary University of London, St. Olavs Hospital, University Hospital of North Norway

Countries where clinical trial is conducted

Austria,  Norway,  Sweden,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	European Quality of Life 5 Dimensions (EQ-5D)	The EQ-5D is a utility instrument for measurement of health-related quality of life.; It consists of 5 dimensions. Each dimension is scored on a level from 1 to 5: LEVEL 1: indicating no problem LEVEL 2: indicating slight problems LEVEL 3: indicating moderate problems LEVEL 4: indicating severe problems LEVEL 5: indicating unable to/extreme; The health state is referred to by a 5-digit code, e.g. state 11111 indicates no problems on any of the five dimensions, while state 55555 indicate extreme problems on all of the five dimensions.	2, 4, 6, 8, 10, 12, 14, 16, 18 months
Other	36-Item Short-form health survey (SF-36)	The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8- scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures and a preference-based health utility index (SF-6D). It is a generic measure, as opposed to one that targets a specific age, disease, or treatment group. Accordingly, the SF-36 has proven useful in surveys of general and specific populations, comparing the relative burden of diseases, and in differentiating the health benefits produced by a wide range of different treatments.	2, 4, 6, 8, 10, 12, 14, 16, 18 months
Other	Work Productivity and Activity Impairment Questionnaire: Rheumatoid Arthritis (WPAI:RA)	The Work Productivity and Activity Impairment (WPAI) questionnaire is a tool that assesses impairments in both work and daily activities. It consists of six items that determine employment status and measure absenteeism caused by health issues, presenteeism, and overall health-related impairment in both paid work and regular activities over the preceding 7 days. The questionnaire yields four outcomes: i) the percentage of work time missed due to health; ii) the percentage of impairment experienced while working due to health in the past 7 days; iii) the percentage of overall work impairment; iv) activity impairment resulting from health issues. Participants will be asked to answer the Work Productivity and Activity Impairment Questionnaire: Rheumatoid Arthritis V2.0.	2, 4, 6, 8, 10, 12, 14, 16, 18 months
Other	Rheumatoid arthritis flare questionnaire (RA-FQ)	The RA-FQ was developed by the Omeract group to identify and measure flares in patients with RA. It encompasses pain, physical impairment, fatigue, stiffness, and participation, and the score is calculated as the sum of responses for the 5 items (maximum 50).	2, 4, 6, 8, 10, 12, 14, 16, 18 months
Other	Adherence	At each visit (every two months), the participant will fill out a questionnaire assessing compliance in into the eCRF.	2, 4, 6, 8, 10, 12, 14, 16, 18 months
Other	Co-medication	Registration of co-medication will be made at each clinical visit.	4, 8, 12, and 18 months
Other	Consentration of C-reactive protein (CRP)	C-reactive protein (CRP) will be measured at all clinical visits.	4, 8, 12, and 18 months
Other	Erythrocyte sedimentation rate (ESR)	Erythrocyte sedimentation rate (ESR) will be measured at all clinical visits.	4, 8, 12, and 18 months
Primary	Sustained disease control over the follow-up period of 18 months without flare	A flare defined as either of the following: A combination of an increase in Disease Activity Score using 28 joints C-reactive protein (DAS28-CRP) > 1.2, or > 0.6 if DAS28-CRP = 3.2, AND 2 swollen joints on examination of 44 joints; OR; Consensus between patient and physician that a disease flare has occurred, leading to a major change* in treatment; *Please see protocol for the definition of a major change in treatment (due to word restrictions)	4, 8, 12, 18 months
Secondary	Disease activity assessed by Disease Activity Score using 28 joints C-reactive protein (DAS28-CRP)	The DAS28-CRP composite score includes the 28 tender and swollen joint counts, CRP and a Patient Global Assessment of Disease activity (PGA).; The DAS28-CRP is calculated as follows: DAS28-CRP = 0.56*v (tender joints 28) + 0.28*v (swollen joints 28) + 0.36*ln(CRP (mg/L)+1) + 0.014*PGA + 0.96 High disease activity is defined as a DAS28-CRP value > 5.1, moderate disease activity as DAS28-CRP > 3.2 - 5.1, low disease activity as a DAS28-CRP-value of 2.6 - 3.2, and remission as DAS28-CRP < 2.6; PGA is measured on a 100 mm VAS according to the question: "Considering all the ways your arthritis has affected you, how did you feel your arthritis was over the last week?" (on a 0-100mm Visual Analogue Scale (VAS) with with 0 = excellent and 100 = very poor).	4, 8, 12, and 18 months
Secondary	Disease activity measured by 44 joint count	44 joint count are included in the original Disease Activity Score (DAS) and in addition to the joints included in DAS28 it includes the MTP joints and the sternoclavicular joints for a more comprehensive valuation of the participants' joints.	4, 8, 12, and 18 months
Secondary	Patient Global assessment of disease activity (PGA)	PGA is measured on a 100 mm VAS according to the question: "Considering all the ways your arthritis has affected you, how did you feel your arthritis was over the last week?" (on a 0-100mm Visual Analogue Scale (VAS) with with 0 = excellent and 100 = very poor).	4, 8, 12, and 18 months
Secondary	Evaluators Global Assessment of Disease Activity (EGA)	EGA is measured on a NRS according to the question "Please rate the patient's overall (global) disease activity", with 0 = best and 10 = worst.	4, 8, 12, and 18 months
Secondary	Disease activity assessed by Clinical Disease Activity Index (CDAI)	CDAI includes the 28 tender and swollen joint counts, Patient Global Assessment of Disease activity (PGA) and Evaluators Global Assessment of Disease Activity (EGA); The formula for CDAI is: swollen joints 28 + tender joints 28 + (PGA (VAS 0-100)/10) + EGA (NRS 0-10).; PGA is measured on a 100 mm VAS according to the question: "Considering all the ways your arthritis has affected you, how did you feel your arthritis was over the last week?" (on a 0-100mm Visual Analogue Scale (VAS) with with 0 = excellent and 100 = very poor).; EGA is measured on a NRS according to the question "Please rate the patient's overall (global) disease activity", with 0 = best and 10 = worst.	4, 8, 12, and 18 months
Secondary	Disease activity assessed by Simple Disease Activity Index (SDAI)	SDAI includes the 28 tender and swollen joint counts, Patient Global Assessment of Disease activity (PGA) and Evaluators Global Assessment of Disease Activity (EGA) and C-reactive protein (CRP).; The formula for SDAI is: swollen joints 28 + tender joints 28 + (PGA(VAS 0-100)/10) + EGA(NRS 0-10) + (CRP (mg/dL)/10).; PGA is measured on a 100 mm VAS according to the question: "Considering all the ways your arthritis has affected you, how did you feel your arthritis was over the last week?" (on a 0-100mm Visual Analogue Scale (VAS) with with 0 = excellent and 100 = very poor).; EGA is measured on a NRS according to the question "Please rate the patient's overall (global) disease activity", with 0 = best and 10 = worst.	4, 8, 12, and 18 months
Secondary	Remission assessed by American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) remission criteria	The ACR/EULAR remission criteria defines a patient in remission when either; the patient is in Boolean 2.0 remission with each of the variables tender joint count, swollen joint count and CRP having a value of =1 and Patient Global Assessment of Disease activity (PGA) having a value = 2 (PGA on a Visual Analogue Scale (VAS)100mm/10 with 0=best and 100= worst, CRP in mg/dl) OR; the SDAI score is = 3.3	4, 8, 12, and 18 months
Secondary	Rheumatoid Arthritis Impact of Disease (RAID)	The RAID questionnaire includes seven domains with the following relative weights: pain (0.21), functional disability (0.16), fatigue (0.15), emotional well-being (0.12), sleep (0.12), coping (0.12) and physical well-being (0.12) each rated on an Numeric Rating Scale (NRS) (0-10 with 0=best and 10=worst). The rates of each domain are weighted and summed to form a score in the range of 0-10	4, 8, 12, and 18 months
Secondary	Evaluation of physical function measured by Modified Health Assessment Questionnaire (MHAQ)	The MHAQ includes eight items covering the physical function of patients with inflammatory joint diseases.; Each item is scored on a categorical 0-3 scale (0=best and 3= worst) and the sum score is divided by 8 to form the MHAQ score 0.0 to 3.0	4, 8, 12, and 18 months
Secondary	Number and type of adverse events (AE)	Assessments of AE	4, 8, 12, and 18 months
Secondary	Drug survival	Drug survival assessed by survival analyses	4, 8, 12, and 18 months
Secondary	Drug consumption	Assessments of drug consumption	18 months
Secondary	Occurrence of anti-drug antibodies (ADAb)	ADAb will be assessed in all serum samples with adalimumab levels <3mg/L.	2, 4, 6, 8, 10, 12, 14, 16, 18 months
Secondary	Serum drug levels	Serum drug levels will be assessed at all visits, both clinical and digital.	2, 4, 6, 8, 10, 12, 14, 16, 18 months